ropivakain bioq pharma 2 mg/ml otopina za infuziju u sustavu za primjenu
bioq pharma b.v., prins bernhardplein 200, amsterdam, nizozemska - ropivakainklorid hidrat - otopina za infuziju u sustavu za primjenu - 2 mg/ml - urbroj: 1 ml otopine za infuziju sadrži ropivakainklorid hidrat što odgovara 2 mg ropivakainklorida
reglan 5 mg/5 ml oralna otopina
alkaloid d.o.o., slavonska avenija 6 a, zagreb, hrvatska - metoklopramidklorid hidrat - oralna otopina - 5 mg/5 ml - urbroj: 5 ml otopine sadrži 5 mg metoklopramidklorida u obliku metoklopramidklorid hidrata
hypnomidate 2 mg/ml otopina za injekciju
piramal critical care b.v., rouboslaan 32, voorschoten, nizozemska - etomidat - otopina za injekciju - 2 mg/ml - urbroj: 1 ml otopine sadrži 2 mg etomidata
moditen depo 25 mg/1 ml otopina za injekciju
krka farma d.o.o. sarajevo - флуфеназин - otopina za injekciju - 25 mg/1 ml - 1 ml otopine za injekciju sadrži: 25 mg flufenazin dekanoata
moditen depo 25 mg/1 ml otopina za injekciju
krka farma d.o.o. sarajevo - флуфеназин - otopina za injekciju - 25 mg/1 ml - 1 ml otopine za injekciju sadrži: 25 mg flufenazin dekanoata
dexamethason krka 4 mg/1 ml otopina za injekciju
krka farma d.o.o. sarajevo - дексаметазон - otopina za injekciju - 4 mg/1 ml - 1 ml otopine za injekciju sadrži: 4 mg deksametazon fosfat (u obliku deksametazonnatrijum fosfata)
vimpat
ucb pharma sa - lakozamida - epilepsija - antiepileptici sredstva, - vimpat je indiciran kao monoterapija i pomoćna terapija u liječenju parcijalnih napadaja s ili bez sekundarne generalizacije kod odraslih, adolescenata i djece od 4 godine s epilepsijom.
lacosamide accord
accord healthcare s.l.u. - lakozamida - epilepsija - antiepileptici sredstva, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
lacosamide ucb
ucb pharma s.a. - lakozamida - epilepsije, djelomično - antiepileptici sredstva, - proizvođač УКБ prikazan kao monoterapija i dodatna terapija u liječenju parcijalnih napadaja napad sa ili bez sekundarne generalizacije kod odrasle, mlade i djecu od 4 godine s epilepsijom.
lacosamide adroiq
extrovis eu ltd. - lakozamida - epilepsija - antiepileptici sredstva, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.